2021-01-03,b'RT @AlertTrade: \xf0\x9f\x94\xb4\xf0\x9f\x94\xb4  You are invited to test drive TradeIdeas PREMIUM features for 2 weeks!\n\nvia \xe2\x9f\xb6 https://t.co/KTosJiYUrC\n\n\xf0\x9f\x93\x8a\n$SPAQ $JAKK $I\xe2\x80\xa6'
2021-01-03,b'\xf0\x9f\x94\xb4\xf0\x9f\x94\xb4  You are invited to test drive TradeIdeas PREMIUM features for 2 weeks!\n\nvia \xe2\x9f\xb6 https://t.co/KTosJiYUrC\n\n\xf0\x9f\x93\x8a\n$SPAQ $JAKK $IDEX $BOXL $TSLA $NKLA $HYLN $HTZ $SPCE $WKHS $AAPL $FB $LGND $ALNY $GERN $ALXN $EXEL $INCY $STEM $CYTX $CTIC $CUR $OSIR $PSTI $OPXA $VNDA $ACOR $SPPI https://t.co/emMGe6WfUz'
2021-01-03,b'StockTwits Trending Alert: Trading recent interest in ALNYLAM PHARMACEUTICALS\xc2\xa0$ALNY https://t.co/t4Xqmn5PUU'
2021-01-02,b'@gamechangercap I don\xe2\x80\x99t think they make it that far without being acquired. It\xe2\x80\x99s a platform play that\xe2\x80\x99s pretty much de-risked. Given big pharma has been plugging holes with big acquisitions lately I expect $ALNY $HZNP or $ASND will be taken out this year. If not I\xe2\x80\x99d be happy with 15-20%/year'
2021-01-02,b'RT @LONGADAP: $ONCS $10 PT Dawson James\xf0\x9f\x9a\x80\n\n$CVAC $BNTX $ALNY $EBS $VIR $ADPT $ARCT $TBIO $VXRT $ATRA $VBIV $ALT $DVAX $IBIO $HTBX $TNXP $NNV\xe2\x80\xa6'
2021-01-02,"b""2020 Return: 53.83% \n\nContinued to reduce software exposure in December and increase bio holdings. \n\nPositions &gt; 1%:\n\n$SNOW $FSLY $PLAN $TXG $NARI $OM $ALNY $HZNP $CCXI $IGMS $KYMR $RLAY\n\nPositions &lt; 1%: \n\n$ALLO $ALVR $ALXO $ANNX $RCUS $ATHA $RNA $BDTX\n$CRIS $DCPH $GBIO\n\ncont'd"""
2021-01-02,b'RT @RNAiAnalyst: RNAi Co $SLN has history of providing updates at beginning of year. \n\nThis year could be 1st knockdown data w/ its GalNAc\xe2\x80\xa6'
2021-01-02,b'RT @RNAiAnalyst: RNAi Co $SLN has history of providing updates at beginning of year. \n\nThis year could be 1st knockdown data w/ its GalNAc\xe2\x80\xa6'
2021-01-02,b'RT @RNAiAnalyst: RNAi Co $SLN has history of providing updates at beginning of year. \n\nThis year could be 1st knockdown data w/ its GalNAc\xe2\x80\xa6'
2021-01-02,b'RT @RNAiAnalyst: RNAi Co $SLN has history of providing updates at beginning of year. \n\nThis year could be 1st knockdown data w/ its GalNAc\xe2\x80\xa6'
2021-01-01,b'RNAi Co $SLN has history of providing updates at beginning of year. \n\nThis year could be 1st knockdown data w/ its GalNAc tech+maybe some partnering news. Stock showed strength last few sessions.\n\n$ALNY $ARWR $DRNA'
2021-01-01,b'@TOWiU2 @maddstone1 @portefeuillefun You make me feel old now: https://t.co/vsgUO8MBTY\n\n$ALNY #lipidoids #LNPs'
2021-01-01,b'My high conviction hold into 2021\n$TDOC\n$TSLA\n$CRNC\n$BAND\n$MAXR\n$SE\n$DOCU\n$JMIA\n$NVDA\n$DKNG\n$SKLZ\n\nBag holding\n$BABA\n$ZM \n$LLNW \xf0\x9f\x98\xab need to get outta this junk\n\nAccumulating BIO stocks\n$ALNY\n$DRNA\n$PSNL\n$ADAP\n$TXQ\n$QURE'
2021-01-01,"b""#401KBeatTheSpy -retirement acc - 401K SDBA gives you lots of flexibility, I like it.\n\n2020: +142.13% - I don't think this is going to last \xf0\x9f\x98\xac\n\nIn order of size $NET $ROKU $NVCR $CRWD $FLGT $BAND $HZNP $PSNL $TDOC $GDRX $ARWR $NARI $ALNY $DDOG $VEEV $GWPH $GBT $BTAI $DRNA $QTNT https://t.co/OwsUgONugx"""
2021-01-01,b'#BeatTheSpy\nPortfolio update - End of 2020\n\n2020: +71.11% / Since 1/1/19:\n+151.39%\n\nLiquidated: ~15% across acc to deploy into school loan \nReduced: $ARWR\nAdded: $ALNY $HZNP\n\nIn order of size $NET $NVCR $ARWR $CRWD $HZNP $FLGT $GWPH $ASND $TDOC $BAND $ALNY $GDRX $AYX $DRNA $QTRX https://t.co/Vlav5rCafS'
2021-01-01,b'BLOOD RED WEEK ENDS 2020.\n\nhttps://t.co/oqnENLGXM4\n\n$MRNA $NVAX $ARCT $BNTX $CVAC $ADPT $ATRA $ALNY $EBS $INO $VXRT $VXRT $ONCS $SRNE $DVAX $ALT $IBIO $IMV $HTBX $TNXP $PDSB $NNVC $VBIV $GNBT $GOVX $VIR #JNJ #MRK #CovidVaccine #covid #PFE $GSK $BMY $ABT #pharma https://t.co/gqtLjzi4KM'
2021-01-01,b'RT @bigpharmaguy: What are key remaining catalysts before end of year? \n$ARVN 110 dose escalation follow up. \n$APRE Ph3 readout \n$SIOX GM1\xe2\x80\xa6'
2021-01-01,b'RT @bigpharmaguy: What are key remaining catalysts before end of year? \n$ARVN 110 dose escalation follow up. \n$APRE Ph3 readout \n$SIOX GM1\xe2\x80\xa6'
2021-01-01,b'26 of 27 COVID VACCINE STOCKS FALL! Bye 2020\n\nhttps://t.co/oqnENLGXM4\n\n$MRNA $NVAX $ARCT $BNTX $CVAC $ADPT $ATRA $ALNY $EBS $INO $VXRT $VXRT $ONCS $NK $SRNE $DVAX $ALT $IBIO $IMV $HTBX $TNXP $PDSB $NNVC $VBIV $GNBT $GOVX $VIR #JNJ #MRK #CovidVaccine #covid #PFE $GSK $BMY $ABT https://t.co/jQQ6GOK1iV'
2020-12-31,b'https://t.co/iiZW2tSnW4 Alnylam Pharmaceuticals Inc Our predictive algorithm foretells that this companie s stock price value is in line with fundamentals in the short term and has a neutral long term price outlook $ALNY #investment #realestate #wallstreet'
2020-12-31,b'$ONCS $10 PT Dawson James\xf0\x9f\x9a\x80\n\n$CVAC $BNTX $ALNY $EBS $VIR $ADPT $ARCT $TBIO $VXRT $ATRA $VBIV $ALT $DVAX $IBIO $HTBX $TNXP $NNVC $PDSB $TFX $GOVX $IGC $MACK $MRUS $XNCR $FPRX $INCY $AGIO $GBT $HALO $ALKS $KPTI $CARA $ZGNX $TMO $EW $DXCM $IDXX $NVTA $HZNP $BMRN $VRTX $ABT $MDT $BSX https://t.co/iddZiroZqJ'
2020-12-31,"b'2006 jointly Andrew Fire and Craig Mello won Noble Prize for RNA interference. The 1st drug was approved in 2018.  In between there was a rise, collapse, and rise in valuations $ALNY $DRNA $ARWR.  Shall we see the same with CRSPR $CRSP $NTLA $EDIT $BEAM?'"
2020-12-31,"b'RT @BikeRieder: $ARWR Biotechs risky to hold through readouts? Yes, small molecules. RNAi? Much better! Look at $ALNY success rate. With Ga\xe2\x80\xa6'"
2020-12-31,b'@3IDWarrant @BikeRieder Actually not surprising given success of the technology. M&amp;A would be prohibitively expensive once a company develops a working platform. $ARWR $ALNY'
2020-12-31,"b'@IBD_AGatlin @menosave $ions will have a dozen trial updates at min, many unpartnered. $CRSP $EDIT $NTLA $ARKK $AMGN $GMAB $XNCR $MGNX $RHHBY $SGEN $GILD $IMGN $MRSN $ZYME $STRO $ARWR $PFE $BNTX $MRNA $TBIO $ARCT $ILMN $EXAS $GH $biib $azn $pfe $mrna $NTRA $arkg $alny @ARKInvest @CathieDWood @Fidelity'"
2020-12-31,"b'Optimus v4\n2020-12-31 10:02 ET. Bought/Opened:\n$ALNY at $129.17. \nAlnylam Pharmaceuticals, Inc (CORP).\nWin Chance: 67%. Avg Win: 6%. Avg Loss: 7.66%. Avg Hold: 10d.\nTrade Id: 63125581103017095.\nStats: https://t.co/oAX4hq6SAg'"
2020-12-31,"b""@menosave That said, there are other companies in this story that aren't CAN SLIM stocks. It's just that RNAi wasn't among the technologies mentioned by experts as being potentially disruptive in 2021. I'm looking forward to what $ARWR, $ALNY and $IONS do next year."""
2020-12-31,b'@BikeRieder Other than $NVS buying Inclisiran for 9.7B there has been no real consolidation in the RNAi space...tons of deals but no M&amp;A...surprising given MOA success $ALNY $ARWR $DRNA $SLN #Platforms'
2020-12-31,"b'RT @BikeRieder: $ARWR Biotechs risky to hold through readouts? Yes, small molecules. RNAi? Much better! Look at $ALNY success rate. With Ga\xe2\x80\xa6'"
2020-12-31,"b'RT @BikeRieder: $ARWR Biotechs risky to hold through readouts? Yes, small molecules. RNAi? Much better! Look at $ALNY success rate. With Ga\xe2\x80\xa6'"
2020-12-31,"b'$ARWR Biotechs risky to hold through readouts? Yes, small molecules. RNAi? Much better! Look at $ALNY success rate. With GalNAc conjugated siRNAs this could be near 100%. This is a Paradigma change. This predictability is of gold value if you\xe2\x80\x99re planning to build a sales force https://t.co/QXNptHBt7E'"
2020-12-31,b'$ALNY buyer at $143.62  -2.62 % change recently https://t.co/0l22j3EB3u'
2020-12-30,b'@SelfThink4 When $ions has a mv of $20 billion+ they might entertain an offer of $35 to 40 billion. With a little luck the former could happen in 2021. $gbt $crsp $auph $tril $tgtx $gild $biib $edit $ntla $dnli $alny $eigr $drrx $fbiox $fgen $tak $mrna $ibb'
2020-12-30,b'$XBI\n$SRPT\n$FOLD\n$NBIX\n$ALNY\n$GWPH\n$CLVS\n$ADMS https://t.co/XMRXKbW2DL'
2020-12-30,b'Mild rebound. \n\nhttps://t.co/oqnENLGXM4\n\n$MRNA $ARCT $NVAX $BNTX $CVAC $ADPT $ATRA $ALNY $EBS $INO $VXRT $VXRT $ONCS $NK $SRNE $DVAX $ALT $IBIO $IMV $HTBX $TNXP $PDSB $NNVC $VBIV $GNBT $GOVX $VIR #JNJ #MRK #CovidVaccine #covid #PFE $GSK $BMY $ABT #pharma https://t.co/nyP2wUfun5'
2020-12-30,b'$ONCS $10 PT Dawson James\xf0\x9f\x9a\x80\n\n$CVAC $BNTX $ALNY $EBS $VIR $ADPT $ARCT $TBIO $VXRT $ATRA $VBIV $ALT $DVAX $IBIO $HTBX $TNXP $NNVC $PDSB $TFX $GOVX $IGC $MACK $MRUS $XNCR $FPRX $INCY $AGIO $GBT $HALO $ALKS $KPTI $CARA $ZGNX $TMO $EW $DXCM $IDXX $NVTA $HZNP $BMRN $VRTX $ABT $MDT $BSX https://t.co/CNWtsWmqa0'
2020-12-30,"b'Stocks with greater movement, last 15 minutes\n\n$AMRN +/- 1.17% Amarin Corporation plc\n$FATE +/- 0.85% Fate Therapeutics Inc.\n$ALNY +/- 0.84% Alnylam Pharmaceuticals Inc.\n$GE +/- 0.61% General Electric Company\n$MRNA +/- 0.57% Moderna Inc.\nhttps://t.co/9y1n8hqFPP'"
2020-12-30,"b'RT @jonesallen234: mRNA $BNTX, $MRNA, $ARCT, Curevac may be the best flavor for anti-viral/COVID19 in the near term... but RNAi offer the b\xe2\x80\xa6'"
2020-12-30,b'$ARWR $DRNA $ALNY - next year may be POC in extrahepatic delivery - I will be passing on $ARKG b/c not a single RNAi company in the fund'
2020-12-30,"b'Optimus v4\n2020-12-30 09:45 ET. *Closed/Sold:\n$ALNY at $133.33 for 2.99 profit (2.29%). Alnylam Pharmaceuticals, Inc (CORP).\nTrade Id: 62951761303066195.\nStats: https://t.co/oAX4hq6SAg'"
2020-12-30,"b'$ALNY technical alerts: 200 DMA Resistance, Fell Below 50 DMA, MACD Bearish Signal Line Cross, Fe... https://t.co/fHjjjEH66J'"
2020-12-30,"b'RT @CompoundNovice: 2020 \xe2\x80\x93 when RNA became mainstream\n\nThe vaccines of Moderna, BioNTech and Curevac have brough mRNA into the spotlight.\xe2\x80\xa6'"
2020-12-29,b'$ARCT collapses. \n\nhttps://t.co/oqnENLGXM4\n\n$MRNA $NVAX $BNTX $CVAC $ADPT $ATRA $ALNY $EBS $INO $VXRT $VXRT $ONCS $SRNE $NK $DVAX $ALT $IBIO $IMV $HTBX $TNXP $PDSB $NNVC $VBIV $GNBT $GOVX $VIR #JNJ #MRK #CovidVaccine #covid #PFE $GSK $BMY $ABT #pharma https://t.co/SXMJOzG690'
2020-12-29,"b'Optimus v4\n2020-12-29 12:35 ET. Bought/Opened:\n$ALNY at $130.29. \nAlnylam Pharmaceuticals, Inc (CORP).\nWin Chance: 71%. Avg Win: 4%. Avg Loss: 6.65%. Avg Hold: 5d.\nTrade Id: 62951761303066195.\nStats: https://t.co/oAX4hq6SAg'"
2020-12-29,"b'RT @CompoundNovice: 2020 \xe2\x80\x93 when RNA became mainstream\n\nThe vaccines of Moderna, BioNTech and Curevac have brough mRNA into the spotlight.\xe2\x80\xa6'"
2020-12-29,"b""2020 \xe2\x80\x93 when RNA became mainstream\n\nThe vaccines of Moderna, BioNTech and Curevac have brough mRNA into the spotlight.\n\nCompanies to watch in this space\nmRNA: $BNTX $MRNA $CVAC $ARCT\nsiRNA (RNAi): $ALNY $ARWR $DRNA $SLN\n\nI'm long ARWR, considering ARCT and SLN https://t.co/fc57yC0JxB"""
2020-12-29,b'$ALNY buyer at $147.39  -2.60 % change recently https://t.co/aSQcF6S6Ua'
2020-12-29,b'Stocks to watch Dec. 29 thru Dec. 31 $gtLs $pntg $carr $fox $tex $mor $eva $kmx $itos $weLL $coLm $spb $fcx $mo $aLny $kLic $odp $hfc $wpm $nni &amp; $EH EHang the catalyst https://t.co/vHnGWbwdsD https://t.co/go3kYXyuwo'
2020-12-28,"b""Some PT's..\n\n$AMZN reit OW, $2100 Piper\n$ALNY 210\xe2\x9e\x9c230 FBR\n$ANDV 148\xe2\x9e\x9c152 JPM\n$DLR 128\xe2\x9e\x9c131 RBC\n$ESTA init.\nBuy $35 Jeff\nOP $35 Cowen\n$MYL 42\xe2\x9e\x9c51 RBC\n$PLNT 40\xe2\x9e\x9c45 Imperial Cap\n$PZZA u/g $52 Longbow\n$RGNX 48\xe2\x9e\x9c83 Barclays\n$RUBY init.\nBuy $40 Jeff\nOW $37 MS\n$TLRY init. OP, $34 Cowen"""
2020-12-28,b'RT @IanGray44757496: Stop the Fogging Problem - what to do when your mask fogs your glasses https://t.co/tf99NlIkVQ via @YouTube \n\n$MRNA $A\xe2\x80\xa6'
2020-12-28,b'Stop the Fogging Problem - what to do when your mask fogs your glasses https://t.co/tf99NlIkVQ via @YouTube \n\n$MRNA $ARCT $BNTX $CVAC $ADPT $ATRA $ALNY $EBS $INO $VXRT $VXRT $ONCS $SRNE $DVAX $ALT $IBIO $IMV $HTBX $TNXP #COVID #VACCINE #CORONAVIRUS $GOVX $GNBT #JNJ $BMY $GSK $WSJ'
2020-12-28,b'COVID VACCINE STOCK CARNAGE! $CVAC and $NK hit\n\nhttps://t.co/oqnENLGXM4\n\n$MRNA $NVAX $ARCT $BNTX $ADPT $ATRA $ALNY $EBS $INO $VXRT $VXRT $ONCS $SRNE $DVAX $ALT $IBIO $IMV $HTBX $TNXP $PDSB $NNVC $VBIV $GNBT $GOVX $VIR #JNJ #MRK #CovidVaccine #covid #PFE $GSK $BMY $ABT #pharma https://t.co/W9Wb7Q1qEI'
2020-12-28,b'200 DMA Support today: $HDSN $TTOO $ALNY $CSCW $AESE $CENT $XIN $ITP ... https://t.co/LjP7KUcNnp'
2020-12-28,b'$PDSB Bio jumps out of BOTTOM TEN.\n\nhttps://t.co/oqnENLGXM4\n\n$MRNA $NVAX $ARCT $BNTX $CVAC $ADPT $ATRA $ALNY $EBS $INO $VXRT $VXRT $ONCS $SRNE $DVAX $ALT $IBIO $IMV $HTBX $TNXP $NNVC $VBIV $GNBT $GOVX $VIR #JNJ #MRK #CovidVaccine #covid #PFE $GSK $BMY $ABT #pharma https://t.co/541G1OvTX6'
2020-12-28,"b'Although the technical rating is only medium, $ALNY does present a nice setup opportunity. https://t.co/ExFnsXUDEQ https://t.co/083Tvk5PTl'"
2020-12-28,b'$ONCS $10 PT Dawson James\xf0\x9f\x9a\x80\n\n$CVAC $BNTX $ALNY $EBS $VIR $ADPT $ARCT $TBIO $VXRT $ATRA $VBIV $ALT $DVAX $IBIO $HTBX $TNXP $NNVC $PDSB $TFX $GOVX $IGC $MACK $MRUS $XNCR $FPRX $INCY $AGIO $GBT $HALO $ALKS $KPTI $CARA $ZGNX $TMO $EW $DXCM $IDXX $NVTA $HZNP $BMRN $VRTX $ABT $MDT $BSX https://t.co/1eDxx2aPXB'
2020-12-28,b'$ONCS $10 PT Dawson James\xf0\x9f\x9a\x80\n\n$CVAC $BNTX $ALNY $EBS $VIR $ADPT $ARCT $TBIO $VXRT $ATRA $VBIV $ALT $DVAX $IBIO $HTBX $TNXP $NNVC $PDSB $TFX $GOVX $IGC $MACK $MRUS $XNCR $FPRX $INCY $AGIO $GBT $HALO $ALKS $KPTI $CARA $ZGNX $TMO $EW $DXCM $IDXX $NVTA $HZNP $BMRN $VRTX $ABT $MDT $BSX https://t.co/WUuJUKPokF'
2020-12-27,b'RT @semodough: $ALNY RNAi therapeutic pipeline goal of filing 2-4 INDs each year. ended 3Q:20 with cash of $1.86 billion likely not need to\xe2\x80\xa6'
2020-12-27,b'$ALNY RNAi therapeutic pipeline goal of filing 2-4 INDs each year. ended 3Q:20 with cash of $1.86 billion likely not need to access the capital markets before reaching profitability.'
2020-12-27,b'RT @TheMarketRoyal: $ALNY looking to push higher if it can hold the breakout https://t.co/TCZoo4Qy3R'
2020-12-27,b'$ALNY looking to push higher if it can hold the breakout https://t.co/TCZoo4Qy3R'
2020-12-27,b'$NK blows up! $NVAX way on top again.\n\nhttps://t.co/oqnENLGXM4\n\n$MRNA $ARCT $BNTX $CVAC $ADPT $ATRA $ALNY $EBS $INO $VXRT $VXRT $ONCS $SRNE $DVAX $ALT $IBIO $IMV $HTBX $TNXP $PDSB $NNVC $VBIV $GNBT $GOVX $VIR #JNJ #MRK #CovidVaccine #covid #PFE $GSK $BMY $ABT #pharma https://t.co/2RxTTsFvrB'
2021-01-07,"b""RT @RNAiAnalyst: In similar vein, it's a relief to know that LNP-based Onpattro by $ALNY (LNP IP licensed from $ABUS) can be repeat-adminis\xe2\x80\xa6"""
2021-01-07,b'Great news for patients and investors this morning \nhttps://t.co/DugRGhrK5m\nLong #RNAiRevolution $ALNY $ARWR $DRNA'
2021-01-07,"b""RT @HelixBioPharma: Alnylam's next-gen ATTR amyloidosis drug hits goals in phase 3, teeing up approval filing! The success sets the RNAi sp\xe2\x80\xa6"""
2021-01-07,"b'RT @BentheFidler: Alnylam, with positive data in hand, prepares to submit 4th drug for approval https://t.co/BZLzFOjjem by @realJacobBell $\xe2\x80\xa6'"
2021-01-07,"b'RT @chunfeng0808: Next generation biotech platform leader:\n1) B-Bio-database: $ILMN, $TXG $TWST 13andme; $ADPT\n2) Gene edit: $CRSP $BEAM, $\xe2\x80\xa6'"
2021-01-07,"b""Alnylam's next-gen ATTR amyloidosis drug hits goals in phase 3, teeing up approval filing! The success sets the RNAi specialist up to file for FDA approval early this year! $ALNY #amyloidosis #RNAi\nhttps://t.co/NxLmULE6sa"""
2021-01-07,"b'RT @BentheFidler: Alnylam, with positive data in hand, prepares to submit 4th drug for approval https://t.co/BZLzFOjjem by @realJacobBell $\xe2\x80\xa6'"
2021-01-07,"b'Alnylam, with positive data in hand, prepares to submit 4th drug for approval https://t.co/BZLzFOjjem by @realJacobBell $ALNY'"
2021-01-07,"b'@jfais20 cell therapy, kinase inhibitors, complement, gene Tx, Antibodies. Try to pick 2 or 3, sometimes more in oncology. That said in RNAi I\xe2\x80\x99m taking $ALNY and leaving the rest.'"
2021-01-07,"b'Next generation biotech platform leader:\n1) B-Bio-database: $ILMN, $TXG $TWST 13andme; $ADPT\n2) Gene edit: $CRSP $BEAM, $EDIT, $NTLA\n3) mRNA and siRNA: $mRNA, $BNTX,$CVAC, $TBIO, $ARWR, $ALNY\n4) Gene therapy: $FOLD, $RGNX, $GBIO;'"
2021-01-07,"b'RT @Steve_382: $ALNY #RNAi The probability of success is so much better than the industry overall. $ARWR $DRNA, etc. https://t.co/IrWbHm9Zka'"
2021-01-07,"b'RT @Steve_382: $ALNY #RNAi The probability of success is so much better than the industry overall. $ARWR $DRNA, etc. https://t.co/IrWbHm9Zka'"
2021-01-07,"b""RT @ByMadeleineA: $ALNY's franchise-extension plan bears fruit with top-line vutrisiran win, but investors await more detailed cardiac data\xe2\x80\xa6"""
2021-01-07,"b'RT @Steve_382: $ALNY #RNAi The probability of success is so much better than the industry overall. $ARWR $DRNA, etc. https://t.co/IrWbHm9Zka'"
2021-01-07,b'$ISR 1.31? OMG! adding!! MASSIVE NEWS. FDA APPROVED! $10 break easy\n\n$IONS $GBT $XON $CRSP $EDIT $NTLA $PBYI $BMRN $TSRO $CELG $BLUE $ALKS $ALNY $GILD $BIIB $AMGN $SGMO $ONCE $ENDP $PRGO $LCI $COLL $ANIP $MYL $OSUR $PODD $BIO $EW $ABT $MDT $ZIOP $KOOL $SRNE $CLLS $JNJ $MARA $RIOT https://t.co/tX1thF4NYY'
2021-01-07,"b'$ALNY #RNAi The probability of success is so much better than the industry overall. $ARWR $DRNA, etc. https://t.co/IrWbHm9Zka'"
2021-01-07,"b""RT @StockMKTNewz: Best performing large cap stocks in today's early trading\n\nPlug Power $PLUG\nCureVac $CVAC\nQuantumScape $QS\n10x $TXG\nCrisp\xe2\x80\xa6"""
2021-01-07,b'RT @semodough: Baml $ALNY view vutrisiran as a best-in-class treatment in hATTR-PN and are optimistic for TTR silencers in cardiomyopathy.\xe2\x80\xa6'
2021-01-07,b'@semodough What was the % knockdown of TTR from baseline? $ALNY'
2021-01-07,"b""$ALNY's franchise-extension plan bears fruit with top-line vutrisiran win, but investors await more detailed cardiac data. Via @evaluatevantage https://t.co/TLEOOgl2ai"""
2021-01-07,"b'RT @jfais20: $XBI $IBB To gain exposure to a particular theme or class of drugs, a \xc2\xa8basket approach\xc2\xa8 is often optimal (balances diversifica\xe2\x80\xa6'"
2021-01-07,b'RT @semodough: Baml $ALNY view vutrisiran as a best-in-class treatment in hATTR-PN and are optimistic for TTR silencers in cardiomyopathy.\xe2\x80\xa6'
2021-01-07,b'Baml $ALNY view vutrisiran as a best-in-class treatment in hATTR-PN and are optimistic for TTR silencers in cardiomyopathy. Raise PT 159'
2021-01-07,"b'$XBI $IBB To gain exposure to a particular theme or class of drugs, a \xc2\xa8basket approach\xc2\xa8 is often optimal (balances diversification, risk and upside)\n\nie equal parts $ALXO $TRIL in CD47\n\n$ARWR $DRNA $ALNY in RNAi\n\nWhat others come to mind for you?'"
2021-01-07,"b""Best performing large cap stocks in today's early trading\n\nPlug Power $PLUG\nCureVac $CVAC\nQuantumScape $QS\n10x $TXG\nCrispr $CRSP\nSnowflake $SNOW\nSunrun $RUN\nSK Telecom $SKM\n$ROKU\nAlnylam $ALNY\nC3 $AI\nCanopy $CGC\nLuminar $LAZR\nConstellation $STZ\nEnphase $ENPH\nLI Auto $LI\n$NIO"""
2021-01-07,b'Rose Above 50 DMA today: $TXG $INCY $FRO $SOS $KROS $MHO $NFLX $GPS $GBT $ALNY $VEEV $OFLX $CTMX $DOCU $USAK $GNUS $COG $FTFT $AIM $LTRX ... https://t.co/qwiJH6vr1O'
2021-01-07,b'RT @RNAiAnalyst: $ALNY out w/ very imp p3 results w/ long-acting subQ version of TTR RNAi drug for FAP (HELIOS-A; neuropathy). Too little d\xe2\x80\xa6'
2021-01-07,"b""$ALNY Alnylam's next-gen ATTR amyloidosis drug hits goals in phase 3, teeing up approval filing https://t.co/Fy5wqcg5jw"""
2021-01-07,"b'Optimus v4\n2021-01-07 09:32 ET. *Closed/Sold:\n$ALNY at $135.90 for 6.39 profit (4.95%). Alnylam Pharmaceuticals, Inc (CORP).\nTrade Id: 63125581103017095.\nStats: https://t.co/oAX4hq6SAg'"
2021-01-07,"b'@bradloncar Another avenue is by taking advantage of the market chasing high flyers $BEAM $CRSP $EDIT $NTLA while ignoring companies using ""older"" tech the quietly keep churning out approvable drugs at a high efficiency $ALNY $IONS - RNAi is absent from ARK ETFs\nhttps://t.co/sVbHcrpMfY'"
2021-01-07,"b""Alnylam's vutrisiran successful in late-stage nerve disorder study $ALNY https://t.co/3gwJ6Rml5h"""
2021-01-07,"b""Alnylam's vutrisiran successful in late-stage nerve disorder study $ALNY https://t.co/hTSz4iUikn"""
2021-01-07,"b""$ALNY - Alnylam's vutrisiran successful in late-stage nerve disorder study https://t.co/3Zc8IBsV0s"""
2021-01-07,b'$ALC +2.7% (launches AcrySof IQ Vivity) \n\n$ALNY +2.1% (reports positive topline results from HELIOS-A phase 3 study of vutrisiran in patients with hATTR amyloidosis with polyneuropathy; met primary and all secondary endpoints at 9 months)'
2021-01-07,b'$ALNY \xe2\x80\x93 Alnylam Intends to Present Full 9-Month Results and File New Drug Application (NDA) in Early 2021 \xe2\x80\x93 https://t.co/BQID5iEdyL'
2021-01-07,b'RT @jonesallen234: RNAi has an inherent advantage by not using LNP in their therapies $ALNY $ARWR $DRNA\nhttps://t.co/Dg2Zv3pycc'
2021-01-07,b'$ALNY: Alnylam Pharma reports positive topline results from HELIOS-A phase 3 study of vutrisiran in patients with... https://t.co/jgzLrQFTXv'
2021-01-07,b'RT @BioStocks: $ALNY Reports Positive Topline Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis with Pol\xe2\x80\xa6'
2021-01-07,b'RNAi has an inherent advantage by not using LNP in their therapies $ALNY $ARWR $DRNA\nhttps://t.co/Dg2Zv3pycc'
2021-01-07,b'RT @govermentchild: $alny resumes trading. Releases phase 3 data. Up big on news'
2021-01-07,b'RT @RNAiAnalyst: $ALNY out w/ very imp p3 results w/ long-acting subQ version of TTR RNAi drug for FAP (HELIOS-A; neuropathy). Too little d\xe2\x80\xa6'
2021-01-07,b'$ALNY (+2.1% pre) Alnylam Reports Positive Topline Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy - BW\n\nhttps://t.co/LINAfa4SsL'
2021-01-07,b'Trading Resumed for $ALNY at 07:30:00 ET on NASDAQ | 2021-01-07'
2021-01-07,b'Trading Halted for $ALNY at 06:55:10 ET on NASDAQ | News and Resumption Times | 2021-01-07'
2021-01-07,b'TRADING HALT: $ALNY via \xe2\x86\x92 https://t.co/BCEHq7Ce2N'
2021-01-07,b'RT @PjvPjwc: $ALNY positive topline results for Phase 3 Helios-A Vutrisiran.'
2021-01-07,b'RT @JohnCendpts: $ALNY\nAlnylam nears FDA filing for 4th RNAi therapy vutrisiran after late-stage data back use in protein misfolding disord\xe2\x80\xa6'
2021-01-07,b'$alny resumes trading. Releases phase 3 data. Up big on news'
2021-01-07,b'$ALNY Alnylam Reports Positive Topline Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy https://t.co/RAIhfhy34R'
2021-01-07,b'RT @RNAiAnalyst: $ALNY out w/ very imp p3 results w/ long-acting subQ version of TTR RNAi drug for FAP (HELIOS-A; neuropathy). Too little d\xe2\x80\xa6'
2021-01-07,"b'Alnylam announces HELIOS-A study met primary, both secondary endpoints\n$ALNY'"
2021-01-07,b'$ALNY out w/ very imp p3 results w/ long-acting subQ version of TTR RNAi drug for FAP (HELIOS-A; neuropathy). Too little detail (e.g. how does it compare to i.v. ONPATTRO; safety questions) to say whether good:\n\nhttps://t.co/vqzxUQWTAy\n\n$IONS'
2021-01-07,b'RT @MSollender: $ALNY Alnylam Reports Positive Topline Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis\xe2\x80\xa6'
2021-01-07,b'$ALNY NEW ARTICLE : Alnylam Reports Positive Topline Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy https://t.co/ZDCOCqthS2 Get all the latest $ALNY related news here : https://t.co/ZEDg9VrCTe https://t.co/sMQ33n9GId'
2021-01-07,b'$ALNY Will resume 07:30:00. News and Resumption Times. (Halted: 06:55:10)'
2021-01-07,b'$ALNY Trading to resume for Alnylam Pharmaceuticals  Inc. (ALNY). Halt Reason: NEWS DISSEMINATED. Resume Time: 01/07/2021 07:30:00\nGet realtime notifications at https://t.co/xHvR7YRLDk'
2021-01-07,b'$ALNY positive topline results for Phase 3 Helios-A Vutrisiran.'
2021-01-07,b'$ALNY Trading Halted for Alnylam Pharmaceuticals  Inc. (ALNY). Halt Reason: NEWS RELEASED.\nGet realtime notifications at https://t.co/xHvR7YRLDk'
2021-01-07,b'$ALNY Halt - News Released. Halt time: 06:55:10.'
2021-01-07,b'RT @JohnCendpts: $ALNY\nAlnylam nears FDA filing for 4th RNAi therapy vutrisiran after late-stage data back use in protein misfolding disord\xe2\x80\xa6'
2021-01-07,b'RT @JohnCendpts: $ALNY\nAlnylam nears FDA filing for 4th RNAi therapy vutrisiran after late-stage data back use in protein misfolding disord\xe2\x80\xa6'
2021-01-07,b'RT @JohnCendpts: $ALNY\nAlnylam nears FDA filing for 4th RNAi therapy vutrisiran after late-stage data back use in protein misfolding disord\xe2\x80\xa6'
2021-01-07,b'RT @MSollender: $ALNY Alnylam Reports Positive Topline Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis\xe2\x80\xa6'
2021-01-07,b'RT @MSollender: $ALNY Alnylam Reports Positive Topline Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis\xe2\x80\xa6'
2021-01-07,b'RT @MSollender: $ALNY Alnylam Reports Positive Topline Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis\xe2\x80\xa6'
2021-01-07,b'$ALNY Alnylam Reports Positive Topline Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy \nhttps://t.co/AJflgfvgaL'
2021-01-07,b'$ALNY\nAlnylam nears FDA filing for 4th RNAi therapy vutrisiran after late-stage data back use in protein misfolding disorder\nBy @ka_blankenship \nhttps://t.co/37fkw1jGUw'
2021-01-07,"b'$ALNY [15s. delayed]: Issued Press Release on January 07, 07:00:00: Alnylam Reports Positive Topline Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy https://t.co/X8soMxOMhX'"
2021-01-07,b'Alnylam Reports Positive Topline Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amylo.. $ALNY $ALNY https://t.co/xdfvvgCLtt'
2021-01-07,b'$ALNY Alnylam Reports Positive Topline Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy\n\nhttps://t.co/KLI8HfAeX0'
2021-01-07,b'RT @BioStocks: $ALNY Reports Positive Topline Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis with Pol\xe2\x80\xa6'
2021-01-07,b'$ALNY Reports Positive Topline Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy.\n\nVutrisiran Met Primary and All Secondary Endpoints at 9 Months'
2021-01-07,b'$ALNY Halt - News Pending. Halt time: 06:55:10.'
2021-01-07,b'RT @_B_I_O_T_E_C_H_: $ALNY  ALNYLAM REPORTS POSITIVE TOPLINE RESULTS FROM HELIOS-A PHASE 3 STUDY OF VUTRISIRAN IN PATIENTS WITH HATTR AMYLO\xe2\x80\xa6'
2021-01-07,b'$ALNY  ALNYLAM REPORTS POSITIVE TOPLINE RESULTS FROM HELIOS-A PHASE 3 STUDY OF VUTRISIRAN IN PATIENTS WITH HATTR AMYLOIDOSIS WITH POLYNEUROPATHY'
2021-01-07,b'RT @BioStocks: $ALNY and $OXFD halted'
2021-01-07,b'$ALNY and $OXFD halted'
2021-01-07,b'$ALNY Trading Halted for Alnylam Pharmaceuticals  Inc. (ALNY). Halt Reason: NEWS PENDING.\nGet realtime notifications at https://t.co/xHvR7YRLDk'
2021-01-07,"b'$ALNY halted , news pending'"
2021-01-07,b'HALTED: $ALNY Date: 2021-01-07 Time: 6:55:10 Code: T1'
2021-01-07,b'Trading Halt: Halted at 6:55:10 AM - Trading Halt: Halt News Pending $ALNY https://t.co/eWywaIjpA0 @benzinga'
2021-01-07,b'$ISR beautiful video describing everything\nhttps://t.co/OH5JYKjQZj\n\n$IONS $GBT $XON $CRSP $EDIT $NTLA $PBYI $BMRN $TSRO $CELG $BLUE $ALKS $ALNY $GILD $BIIB $AMGN $SGMO $ONCE $ENDP $PRGO $LCI $COLL $ANIP $MYL $OSUR $PODD $BIO $EW $ABT $MDT $ZIOP $KOOL $SRNE $CLLS $JNJ $MARA $RIOT'
2021-01-07,"b'All of our tickers for tomorrow, be careful it may be super red:\n\nhttps://t.co/Ww31MloBsJ\n\n$ALNY\n$ATNX\n$BAND\n$BILL\n$CDW\n$EBR\n$FGEN\n$PSA\n$SDC\n$SUI\n$VRSN'"
2021-01-06,b'Big Ones lead $MRNA $NVAX $BNTX up\n\nhttps://t.co/oqnENLGXM4\n\n$ARCT $CVAC $ADPT $ATRA $ALNY $EBS $INO $VXRT $VXRT $ONCS $SRNE $DVAX $ALT $IBIO $IMV $HTBX $TNXP $PDSB $NNVC $VBIV $GNBT $GOVX $VIR #JNJ #MRK #CovidVaccine #covid #PFE $GSK $BMY $ABT #pharma https://t.co/C42TXEYllo'
2021-01-06,"b'RT @TradeWithAlerts: Large Print $ALNY Size: 111516 Price: 126.83 Time: 1600 Amount: $14,143,574.28'"
2021-01-06,"b'Large Print $ALNY Size: 111516 Price: 126.83 Time: 1600 Amount: $14,143,574.28'"
2021-01-06,b'@Biotech2k1 I would start with RNAi companies - ARK does not hold a single one in its funds - $ALNY $DRNA $ARWR $SLN'
2021-01-06,b'$XBI up 3% now and $ALNY flat. ARWR also up almost 3%. Seems like Alnylam should be following these moves.'
2021-01-06,"b'$ions $alny $biib $azn $amgn $regn l think it speaks just to the enormous potential that drugging #RNA has, unlocking an entirely new set of drugs for the industry would be huge,\xe2\x80\x9d says #Ribometrix CEO Solomon, 15 mos after inking a deal to work with $vrtx  https://t.co/XZFEs9qHIU'"
2021-01-06,b'RT @biostonks: A list of mRNA players $MRNS $BNTX $ALNY $CVAC $SRPT $CRSP $IONS $ARWR $NTLA $ARTC $DRNA $TBIO $RNA $DTLA $SLN $HOOK $ABUS $\xe2\x80\xa6'
2021-01-06,"b'A list of mRNA players $MRNS $BNTX $ALNY $CVAC $SRPT $CRSP $IONS $ARWR $NTLA $ARTC $DRNA $TBIO $RNA $DTLA $SLN $HOOK $ABUS $VYGR $PRQR $ELOX $XCUR $BNTC if you want one added provide a link so I can read it, thanks https://t.co/mdFwZzwGjb'"
2021-01-06,b'$ISR MASSIVE FDA NEWS gonna break $3 today\xf0\x9f\x92\xb8\n\n$IONS $GBT $XON $CRSP $EDIT $NTLA $PBYI $BMRN $TSRO $CELG $BLUE $ALKS $ALNY $GILD $BIIB $AMGN $SGMO $ONCE $ENDP $PRGO $LCI $COLL $ANIP $EGRX $MYL $OSUR $PODD $TNDM $BIO $EW $ABT $MDT $ZIOP $KOOL $SRNE $CLLS $JNJ $MARA $RIOT $NVCR $AMT https://t.co/dfy8gbIY1u'
